Symbols

Symbols

PMVP

PMVP

PMV Pharmaceuticals' Cash Burn: Assessing Its Growth Potential

Monday Oct 27, 2025

ORBIMED ADVISORS Sells 1M PMV Pharmaceuticals Shares at $1.52 on Oct 23, 2023.

Friday Oct 24, 2025

PMV Pharma reports 34% ORR in 103 evaluable patients across all cohorts.

Thursday Sep 18, 2025

Orbimed Advisors Sells 500,000 PMV Pharmaceuticals Shares, Reduces Holdings by 7.72%

Thursday Sep 11, 2025

PMV Pharmaceuticals' Rezatapopt Shows Promising Responses in 8 Tumor Types

Wednesday Sep 10, 2025

Pmv Pharmaceuticals shares rise 6.29% after-hours after promising Phase 2 clinical trial data for Rezatapopt.

PMV Pharmaceuticals' Cancer Drug Shows Promising Interim Data in Phase 2 Trial

Bazis Pharmaceuticals Updates Rezatapopt Clinical Trial Timeline, Plans NDA Submission

Pmv Pharmaceuticals shares fall 9.06% intraday after announcing PYNNACLE Phase 2 trial interim data and NDA submission plans for Rezatapopt.

PMV Pharma reports 33% ORR in Phase 2 interim data, plans NDA submission in 2027.

Monday Aug 11, 2025

TD Cowen Analyst Maintains Buy Rating for Rallybio.

Thursday Aug 07, 2025

PMV Pharmaceuticals Q2 Loss Jumps Amid Increased R&D Spending

PMV Pharmaceuticals Reports Q2 GAAP EPS of -$0.41, Misses by $0.02

PMV Pharma reports Q2 cash of $148.3mln, expected runway to 2026.

Thursday Jul 03, 2025

PMV Pharmaceuticals Executives Sell Shares at $1.06/Share on July 1, 2025

Sunday May 25, 2025

PMV Pharmaceuticals to Present at Investor Conferences: Precision Oncology Focus Highlighted

Saturday May 10, 2025

PMV Pharmaceuticals Reports Q1 Cash Position and Operational Spending

PMV Pharmaceuticals' PYNNACLE Trial Progressing Steadily, Analysts Predict 541.17% Upside

Friday May 09, 2025

PMV Pharmaceuticals Posts Q1 GAAP EPS of -$0.34, Exceeding Expectations by $0.03, with $165.8 Million in Cash and Marketable Securities as of March 31, 2025.

PMV Pharma reports Q1 revenue, cash $165.8 mln, Phase 2 trial on track.